The Long-Term Prognostic Significance of 6-Minute Walk Test Distance in Patients with Chronic Heart Failure
Table 1
Baseline characteristics of patients mean (SD) divided by survival to >5 years.
Variables
Dead
Alive
value
Age (years)
74.1 (8.9)
67.9 (10.6)
<0.0001
Males (%)
73
75
0.184
BMI (kg·m−2)
27.7 (5.7)
28.9 (5.6)
<0.0001
NYHA class
<0.0001
I/II
36
64
III/IV
58
42
LVEF (%)
33 (10)
36 (9)
<0.0001
FEV1/FVC (%)
66 (16)
70 (16)
<0.0001
Resting HR (beats·min−1)
76 (18)
74 (20)
0.165
Resting systolic BP (mmHg)
132 (26)
133 (24)
0.158
Resting diastolic BP (mmHg)
74 (14)
78 (14)
<0.0001
QRS duration (ms)
121 (32)
112 (29)
<0.0001
Haemoglobin (g·dL−1)
13.0 (1.7)
13.9 (1.5)
<0.0001
Log NT pro-BNP*
7.7 (1.2)
6.7 (1.3)
<0.0001
Sodium (mmol·L−1)
139 (4)
139 (3)
0.652
Potassium (mmol·L−1)
4.4 (0.5)
4.4 (0.5)
0.777
Urea (mmol·L−1)
9.3 (4.7)
7.1 (3.6)
<0.0001
Creatinine (u·moL−1)
130 (51)
110 (55)
<0.0001
Diuretic (%)
83
84
0.760
ACE-inhibitor (%)
78
77
0.348
Beta-blocker (%)
73
69
0.322
Spironolactone (%)
22
20
0.202
6-MWT (m)
163 (153)
269 (160)
<0.0001
NYHA: New York Heart Association; BMI: body mass index; LVI: left ventricular impairment; LVEF*: left ventricular ejection fraction available in 67% of patients; 6-MWT: 6-min walk test; BP: blood pressure; log NT pro-BNP (pg·mL−1)* available in 92% of patients.
